Weiqiang Lu Selected Research

Pharmaceutical Preparations

2/2022	A Novel Small Molecular Prostaglandin Receptor EP4 Antagonist, L001, Suppresses Pancreatic Cancer Metastasis.
1/2021	Targeting Pyrimidine Metabolism in the Era of Precision Cancer Medicine.
1/2020	Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes.
1/2019	A genome-wide positioning systems network algorithm for in silico drug repurposing.
1/2018	Quantitative and systems pharmacology 2. In silico polypharmacology of G protein-coupled receptor ligands via network-based approaches.
1/2017	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
12/2016	In silico prediction of chemical mechanism of action via an improved network-based inference method.
11/2014	Small molecule 1'-acetoxychavicol acetate suppresses breast tumor metastasis by regulating the SHP-1/STAT3/MMPs signaling pathway.
8/2013	The efficient expression of human fibroblast collagenase in Escherichia coli and the discovery of flavonoid inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Weiqiang Lu Research Topics

Disease

25	Neoplasms (Cancer) 10/2022 - 04/2011
4	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2012
3	Neoplasm Metastasis (Metastasis) 02/2022 - 11/2014
3	Carcinoma (Carcinomatosis) 01/2022 - 07/2016
3	Carcinogenesis 01/2021 - 01/2017
3	Inflammation (Inflammations) 01/2021 - 04/2011
3	Lung Neoplasms (Lung Cancer) 01/2018 - 01/2016
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 01/2015
3	Malaria 04/2014 - 01/2009
2	Pancreatic Neoplasms (Pancreatic Cancer) 02/2022 - 10/2019
2	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 01/2016
2	Triple Negative Breast Neoplasms 01/2021 - 01/2019
2	Systemic Scleroderma (Systemic Sclerosis) 01/2021 - 02/2020
2	Fibrosis (Cirrhosis) 01/2021 - 02/2020
2	Lymphatic Metastasis 08/2018 - 02/2017
2	Drug-Related Side Effects and Adverse Reactions 01/2018 - 12/2016
2	Leukemia 01/2018 - 01/2016
2	Acute Lung Injury 01/2017 - 01/2016
1	Disease Progression 03/2022
1	Pain (Aches) 03/2022
1	Osteoarthritis 03/2022
1	Osteophyte 03/2022
1	Colitis 01/2022
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022
1	Colorectal Neoplasms (Colorectal Cancer) 11/2021
1	Neuroinflammatory Diseases 01/2021
1	Alzheimer Disease (Alzheimer's Disease) 01/2021
1	Melanoma (Melanoma, Malignant) 10/2020
1	Multiple Sclerosis 01/2020
1	Autoimmune Diseases (Autoimmune Disease) 01/2020
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2020
1	Chronic Pain 11/2019
1	Hyperalgesia 11/2019
1	Adenocarcinoma of Lung 01/2019
1	Cardiac Arrhythmias (Arrythmia) 01/2019
1	Heart Failure 01/2019
1	Type 2 Diabetes Mellitus (MODY) 10/2018

Drug/Important Bio-Agent (IBA)

9	Pharmaceutical PreparationsIBA 02/2022 - 08/2013
5	Biological ProductsIBA 10/2020 - 05/2011
4	Proteins (Proteins, Gene)FDA Link 02/2022 - 01/2016
4	Dihydroorotate DehydrogenaseIBA 01/2022 - 01/2018
3	Dinoprostone (PGE2)FDA Link 03/2022 - 01/2022
2	ProstaglandinsIBA 01/2022 - 01/2020
2	celastrolIBA 01/2021 - 02/2020
2	Bleomycin (Blenoxane)FDA LinkGeneric 01/2021 - 02/2020
2	Therapeutic UsesIBA 01/2020 - 01/2020
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018 - 07/2016
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 10/2017
2	Tyrosine Kinase InhibitorsIBA 01/2018 - 10/2017
2	Leukotriene B4IBA 01/2017 - 01/2016
2	Cisplatin (Platino)FDA LinkGeneric 07/2016 - 01/2015
2	EnzymesIBA 01/2016 - 08/2013
2	Antimalarials (Antimalarial Agents)IBA 04/2014 - 01/2012
1	Interleukin-2 (IL2)IBA 10/2022
1	Adenosine A2 Receptor AntagonistsIBA 10/2022
1	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 10/2022
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 03/2022
1	Netrin-1IBA 03/2022
1	Gemcitabine FDA Link 02/2022
1	Prostaglandin Receptors (Prostaglandin Receptor)IBA 02/2022
1	Immune Checkpoint ProteinsIBA 01/2022
1	ChemokinesIBA 01/2022
1	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 01/2022
1	AntibodiesIBA 01/2022
1	Dextran SulfateIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 11/2021
1	Sirtuin 1IBA 01/2021
1	CB2 Cannabinoid ReceptorIBA 01/2021
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2021
1	Estrogen Receptor alphaIBA 01/2021
1	Anti-Allergic Agents (Antiallergic Agents)IBA 01/2021
1	desloratadine (Aerius)FDA LinkGeneric 01/2021
1	Designer DrugsIBA 01/2021
1	pyrimidineIBA 01/2021
1	abemaciclibIBA 01/2021
1	CannabinoidsIBA 01/2021
1	shikoninIBA 01/2021
1	Hormones (Hormone)IBA 01/2021
1	gambogic acidIBA 01/2021
1	corynolineIBA 10/2020
1	Caspase 3 (Caspase-3)IBA 10/2020
1	Cysteine (L-Cysteine)FDA Link 10/2020
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 02/2020
1	indium-bleomycinIBA 02/2020
1	ArrestinIBA 02/2020
1	Topotecan (Hycamtin)FDA LinkGeneric 01/2020
1	piperineIBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Analgesics (Analgesic Drugs)IBA 11/2019
1	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 11/2019
1	Transient Receptor Potential ChannelsIBA 11/2019
1	triptolideIBA 10/2019
1	Ouabain (G Strophanthin)IBA 01/2019
1	Angiogenesis InhibitorsIBA 01/2019
1	wogonosideIBA 01/2019
1	Nonesterified Fatty Acids (NEFA)IBA 10/2018

Therapy/Procedure

10	Therapeutics 11/2021 - 05/2011
5	Immunotherapy 10/2022 - 01/2020
4	Drug Therapy (Chemotherapy) 02/2022 - 01/2015
3	Oral Administration 01/2022 - 01/2018